MBX Biosciences, Inc. (MBX)
33.44
+2.46
(+7.92%)
USD |
NASDAQ |
Jun 11, 10:30
MBX Biosciences Debt to Equity Ratio : 0.0013 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.0013 |
| December 31, 2025 | 0.0016 |
| September 30, 2025 | 0.0016 |
| June 30, 2025 | 0.003 |
| March 31, 2025 | 0.0006 |
| Date | Value |
|---|---|
| December 31, 2024 | 0.0008 |
| September 30, 2024 | 0.001 |
| June 30, 2024 | 0.0069 |
| March 31, 2024 | 0.0068 |
| December 31, 2023 | 0.0065 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ANI Pharmaceuticals, Inc. | 1.092 |
| Corcept Therapeutics, Inc. | 0.0151 |
| Assertio Holdings, Inc. | 0.533 |
| Veru, Inc. | 0.0815 |
| Johnson & Johnson | 0.6773 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 452.70M |
| Total Liabilities (Quarterly) | 14.94M |
| Shareholders Equity (Quarterly) | 437.76M |
| Current Ratio | 30.79 |
| Net Debt Paydown Yield | -0.00% |